

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
1	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
2	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		66	Amount as approved by the Audit Committee.			66	-	-	-		-	-	-	-	-	-	-	
3	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		131	Amount as approved by the Audit Committee.			131	-	-	-		-	-	-	-	-	-	-	
4	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
5	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
6	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services		9	Amount as approved by the Audit Committee.			9	-	-	-		-	-	-	-	-	-	-	
7	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
8	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Purchase of goods or services		9	Amount as approved by the Audit Committee.			9	-	-	-		-	-	-	-	-	-	-	
9	Zydus Lifesciences Limited	Sterling Biotech Limited	Joint Ventures	Purchase of goods or services		16	Amount as approved by the Audit Committee.			16	-	-	-		-	-	-	-	-	-	-	
10	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
11	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		399	Amount as approved by the Audit Committee.			399	-	-	-		-	-	-	-	-	-	-	
12	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Purchase of fixed assets		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
13	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Purchase of fixed assets		14	Amount as approved by the Audit Committee.			14	-	-	-		-	-	-	-	-	-	-	
14	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		13	Amount as approved by the Audit Committee.			13	-	-	-		-	-	-	-	-	-	-	
15	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
16	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
17	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		807	Amount as approved by the Audit Committee.			807	-	-	-		-	-	-	-	-	-	-	
18	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		35	Amount as approved by the Audit Committee.			35	-	-	-		-	-	-	-	-	-	-	
19	Zydus Lifesciences Limited	Vitely Bio LLP	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
20	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
21	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
22	Zydus Lifesciences Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-	
23	Zydus Lifesciences Limited	International Tax & Investment Consultants- Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-	
24	Zydus Lifesciences Limited	Sahyadri Hospitals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
25	Zydus Lifesciences Limited	Apollo Healthco Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		10	Amount as approved by the Audit Committee.			10	-	-	-		-	-	-	-	-	-	-	
26	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		50	Amount as approved by the Audit Committee.			50	-	-	-		-	-	-	-	-	-	-	
27	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	422	Amount as approved by the Audit Committee.			422	-	-	-		-	-	-	-	-	-	-	
28	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	40	Amount as approved by the Audit Committee.			40	-	-	-		-	-	-	-	-	-	-	
29	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
30	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	13	Amount as approved by the Audit Committee.			13	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
31	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	11	Amount as approved by the Audit Committee.			11	-	-	-		-	-	-	-	-	-	-	
32	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	183	Amount as approved by the Audit Committee.			183	-	-	-		-	-	-	-	-	-	-	
33	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	82	Amount as approved by the Audit Committee.			82	-	-	-		-	-	-	-	-	-	-	
34	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-	
35	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	19	Amount as approved by the Audit Committee.			19	-	-	-		-	-	-	-	-	-	-	
36	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
37	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	14	Amount as approved by the Audit Committee.			14	-	-	-		-	-	-	-	-	-	-	
38	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses paid	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
39	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Reimbursement of Expenses paid	4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-	
40	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Reimbursement of Expenses Recovered	6	Amount as approved by the Audit Committee.			6	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
41	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
42	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		153	Amount as approved by the Audit Committee.			153	-	-	-		-	-	-	-	-	-	-	
43	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
44	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		411	Amount as approved by the Audit Committee.			411	-	-	-		-	-	-	-	-	-	-	
45	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		57,371	Amount as approved by the Audit Committee.			57,371	-	-	-		-	-	-	-	-	-	-	
46	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		1,821	Amount as approved by the Audit Committee.			1,821	-	-	-		-	-	-	-	-	-	-	
47	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Sale of goods or services		275	Amount as approved by the Audit Committee.			275	-	-	-		-	-	-	-	-	-	-	
48	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-	
49	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		338	Amount as approved by the Audit Committee.			338	-	-	-		-	-	-	-	-	-	-	
50	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Sale of goods or services		810	Amount as approved by the Audit Committee.			810	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
51	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Sale of goods or services		602	Amount as approved by the Audit Committee.			602	-	-	-		-	-	-	-	-	-	-	
52	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Sale of goods or services		313	Amount as approved by the Audit Committee.			313	-	-	-		-	-	-	-	-	-	-	
53	Zydus Lifesciences Limited	Laboratorios Combi S.L.	Subsidiary Company	Sale of goods or services		145	Amount as approved by the Audit Committee.			145	-	-	-		-	-	-	-	-	-	-	
54	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		180	Amount as approved by the Audit Committee.			180	-	-	-		-	-	-	-	-	-	-	
55	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		1,650	Amount as approved by the Audit Committee.			1,650	-	-	-		-	-	-	-	-	-	-	
56	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		14	Amount as approved by the Audit Committee.			14	-	-	-		-	-	-	-	-	-	-	
57	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
58	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
59	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of fixed assets		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
60	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		(13)	Amount as approved by the Audit Committee.			(13)	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
61	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of fixed assets		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
62	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Sale of goods or services		4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-	
63	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		9	Amount as approved by the Audit Committee.			9	-	-	-		-	-	-	-	-	-	-	
64	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		3	Amount as approved by the Audit Committee.			3	-	-	-		-	-	-	-	-	-	-	
65	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		5	Amount as approved by the Audit Committee.			5	-	-	-		-	-	-	-	-	-	-	
66	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
67	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Sale of goods or services		18	Amount as approved by the Audit Committee.			18	-	-	-		-	-	-	-	-	-	-	
68	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		179	Amount as approved by the Audit Committee.			179	-	-	-		-	-	-	-	-	-	-	
69	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		16	Amount as approved by the Audit Committee.			16	-	-	-		-	-	-	-	-	-	-	
70	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		4	Amount as approved by the Audit Committee.			4	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
71	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		35	Amount as approved by the Audit Committee.			35	-	-	-		-	-	-	-	-	-	-	
72	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		2	Amount as approved by the Audit Committee.			2	-	-	-		-	-	-	-	-	-	-	
73	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		31	Amount as approved by the Audit Committee.			31	-	-	-		-	-	-	-	-	-	-	
74	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		64	Amount as approved by the Audit Committee.			64	-	-	-		-	-	-	-	-	-	-	
75	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-	
76	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Investment		-	N.A.			1,395	-	1,395	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
77	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
78	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	2	-		-	-	-	-	-	-	-	
79	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Sale of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
80	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Sale of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
81	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	67	Amount as approved by the Audit Committee.			67	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
														Amount in INR Million except stated otherwise								
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
82	Zydus Lifesciences Limited	Zynext Ventures Pte. Ltd.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
83	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Interest received		-	N.A.			6	-	-	-		-	-	-	-	-	-	-	
84	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Loan		-	N.A.			1,745	-	-	-		-	-	Loans	6 Month SOFR + 240 BPS	5 Year	Unsecured	Business Purpose	
85	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	-	1,715	-		-	-	-	-	-	-	-	
86	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	300	Amount as approved by the Audit Committee.			300	-	-	-		-	-	-	-	-	-	-	
87	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
88	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
89	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
90	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	24	Amount as approved by the Audit Committee.			24	-	-	-		-	-	-	-	-	-	-	
91	Zydus Lifesciences Limited	Mr. Pankaj R. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			1	-	-	-		-	-	-	-	-	-	-	
92	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Remuneration		-	N.A.			210	-	-	-		-	-	-	-	-	-	-	
93	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Remuneration		-	N.A.			70	-	-	-		-	-	-	-	-	-	-	
94	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Remuneration		-	N.A.			47	-	-	-		-	-	-	-	-	-	-	
95	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Remuneration		-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
96	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
97	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Interest received		-	N.A.			347	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
98	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.			243	-	-	-		-	-	-	-	-	-		
99	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.			257	-	-	-		-	-	-	-	-	-		
100	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Interest received		-	N.A.			238	-	-	-		-	-	-	-	-	-		
101	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		84	Amount as approved by the Audit Committee.			84	-	-	-		-	-	-	-	-	-		
102	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Interest received		-	N.A.			7	-	-	-		-	-	-	-	-	-		
103	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Interest paid		-	N.A.			39	-	-	-		-	-	-	-	-	-		
104	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Interest paid		-	N.A.			421	-	-	-		-	-	-	-	-	-		
105	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Interest paid		-	N.A.			1,399	-	-	-		-	-	-	-	-	-		
106	Zydus Lifesciences Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Advance for CSR	-	N.A.			204	-	-	-		-	-	-	-	-	-		
107	Zydus Lifesciences Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Corporate Social Responsibility (CSR) Expenses	-	N.A.			348	-	-	-		-	-	-	-	-	-		
108	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Loan		-	N.A.			4,661	-	-	-		-	-	Loans	1 Month SOFR + 180 BPS	5 Year	Unsecured	Business Purpose	
109	Zydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-		
110	Zydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	4	4	-		-	-	-	-	-	-		
111	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Investment		-	N.A.			550	7,050	7,600	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
112	Zydus Lifesciences Limited	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Investment		-	N.A.			-	84	-	-		-	-	-	-	-	-		
113	Zydus Lifesciences Limited	Zynext Ventures Pte. Ltd.	Subsidiary Company	Investment		-	N.A.			436	360	797	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
114	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Loan		-	N.A.			4,623	-	-	-		-	-	-	-	-	-		
115	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Loan		-	N.A.			1,272	-	-	-		-	-	-	-	-	-		
116	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.			1,743	-	-	-		-	-	-	-	-	-		
117	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Loan		-	N.A.			192	-	-	-		-	-	-	-	-	-		
118	Zydus Lifesciences Limited	Cadila Healthcare Ltd. Managerial Cadre EPF	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			275	-	-	-		-	-	-	-	-	-		
119	Zydus Lifesciences Limited	Cadila Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			480	-	-	-		-	-	-	-	-	-		
120	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	11,670	11,451	-		-	-	-	-	-	-		

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
121	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	36,638	42,347	-		-	-	-	-	-	-	-	
122	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	1,037	1,035	-		-	-	-	-	-	-	-	
123	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	470	442	-		-	-	-	-	-	-	-	
124	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	135	11	-		-	-	-	-	-	-	-	
125	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	401	379	-		-	-	-	-	-	-	-	
126	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	733	650	-		-	-	-	-	-	-	-	
127	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	37	62	-		-	-	-	-	-	-	-	
128	Zydus Lifesciences Limited	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	-	-		-	-	-	-	-	-	-	
129	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	75	75	-		-	-	-	-	-	-	-	
130	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	302	291	-		-	-	-	-	-	-	-	
131	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	48	60	-		-	-	-	-	-	-	-	
132	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	60	79	-		-	-	-	-	-	-	-	
133	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	273	249	-		-	-	-	-	-	-	-	
134	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2	2	-		-	-	-	-	-	-	-	
135	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
136	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	0	-		-	-	-	-	-	-		
137	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	-	-		-	-	-	-	-	-		
138	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	88	13	-		-	-	-	-	-	-		
139	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	10	15	-		-	-	-	-	-	-		
140	Zydus Lifesciences Limited	Sterling Biotech Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	15	7	-		-	-	-	-	-	-		
141	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	61	2	-		-	-	-	-	-	-		
142	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	0	-		-	-	-	-	-	-		
143	Zydus Lifesciences Limited	Vitely Bio LLP	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	0	-		-	-	-	-	-	-		
144	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-		
145	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	1	-		-	-	-	-	-	-		
146	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	141	113	-		-	-	-	-	-	-		
147	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	25	10	-		-	-	-	-	-	-		

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
148	Zydus Lifesciences Limited	Aleta Hospitals LLP [Formerly known as Zydus Hospitals (Vadodara) LLP]	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
149	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	196	-		-	-	-	-	-	-	-	
150	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	82	-		-	-	-	-	-	-	-	
151	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	3	-		-	-	-	-	-	-	-	
152	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-	
153	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	2	3	-		-	-	-	-	-	-	-	
154	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	230	228	-		-	-	-	-	-	-	-	
155	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	13,405	12,582	-		-	-	-	-	-	-	-	
156	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	13,822	9,396	-		-	-	-	-	-	-	-	
157	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	5,445	10,250	-		-	-	-	-	-	-	-	
158	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	9,765	8,263	-		-	-	-	-	-	-	-	
159	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	204	242	-		-	-	-	-	-	-	-	
160	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	4	1	-		-	-	-	-	-	-	-	
161	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	11	1	-		-	-	-	-	-	-	-	
162	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	4	5	-		-	-	-	-	-	-	-	
163	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	104	74	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
164	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	3	1	-		-	-	-	-	-	-		
165	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	595	295	-		-	-	-	-	-	-		
166	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	37,989	61,770	-		-	-	-	-	-	-		
167	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,344	1,797	-		-	-	-	-	-	-		
168	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	47	17	-		-	-	-	-	-	-		
169	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	291	210	-		-	-	-	-	-	-		
170	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	841	702	-		-	-	-	-	-	-		
171	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	908	1,012	-		-	-	-	-	-	-		
172	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	877	1,371	-		-	-	-	-	-	-		
173	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1,254	1,791	-		-	-	-	-	-	-		
174	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	716	893	-		-	-	-	-	-	-		
175	Zydus Lifesciences Limited	Etna Biotech S.R.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	76	76	-		-	-	-	-	-	-		
176	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	131	96	-		-	-	-	-	-	-		
177	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	236	248	-		-	-	-	-	-	-		
178	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	227	409	-		-	-	-	-	-	-		

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
179	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	10	8	-		-	-	-	-	-	-	-	
180	Zydus Healthcare Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
181	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
182	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
183	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
184	Zydus Healthcare Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
185	Zydus Healthcare Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		62	Amount as approved by the Audit Committee.			62	-	-	-		-	-	-	-	-	-	-	
186	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		18	Amount as approved by the Audit Committee.			18	-	-	-		-	-	-	-	-	-	-	
187	Zydus Healthcare Limited	Ramanbhai Foundation	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
188	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		8	Amount as approved by the Audit Committee.			8	-	-	-		-	-	-	-	-	-	-	
189	Zydus Healthcare Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
190	Zydus Healthcare Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
191	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest received		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
192	Zydus Healthcare Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Corporate Social Responsibility (CSR) Expenses	-	N.A.			147	-	-	-		-	-	-	-	-	-	-	
193	Zydus Healthcare Limited	Zydus Foundation	Subsidiary Company	Sale of goods or services		0	Amount as approved by the Audit Committee.			0	-	-	-		-	-	-	-	-	-	-	
194	Zydus Healthcare Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-	
195	Zydus Healthcare Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Advance for CSR	-	N.A.			150	-	-	-		-	-	-	-	-	-	-	
196	Zydus Healthcare Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Investment		-	N.A.			901	-	-	-		-	-	-	-	-	-	-	
197	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.			6,896	-	-	-		-	-	Loans	1 Month T Bill + 35 BPS	5 Year	Unsecured	Business Purpose	
198	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			300	-	-	-		-	-	Loans	0	2 Month	Unsecured	Business Purpose	
199	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			300	-	-	-		-	-	-	-	-	-	-	
200	Zydus Healthcare Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	Share of profit Received	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
201	Zydus Healthcare Limited	Zydus Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			52	-	-	-		-	-	-	-	-	-	-	
202	Zydus Healthcare Limited	Zydus Wellness Limited	Subsidiary Company	Loan		-	N.A.			700	-	-	-		-	-	Loans	1 Year T bill + 90 bps	1 Year	Unsecured	Business Purpose	
203	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
204	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	1	-		-	-	-	-	-	-	-	
205	Zydus Healthcare Limited	Ramanbhai Foundation	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-	
206	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	11	8	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
207	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		82	Amount as approved by the Audit Committee.			82	-	-	-		-	-	-	-	-	-	-	
208	Zydus Wellness Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
209	Zydus Wellness Limited	Zydus Healthcare Limited	Subsidiary Company	Loan		-	N.A.			350	-	-	-		-	-	-	-	-	-	-	
210	Zydus Wellness Limited	Zydus Healthcare Limited	Subsidiary Company	Interest paid		-	N.A.			18	-	-	-		-	-	-	-	-	-	-	
211	Zydus Wellness Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	-	358	-		-	-	-	-	-	-	-	
212	Zydus Wellness Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Corporate Social Responsibility (CSR) Expenses	-	N.A.			6	-	-	-		-	-	-	-	-	-	-	
213	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		1,417	Amount as approved by the Audit Committee.			1,417	-	-	-		-	-	-	-	-	-	-	
214	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		21	Amount as approved by the Audit Committee.			21	-	-	-		-	-	-	-	-	-	-	
215	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of fixed assets		1	Amount as approved by the Audit Committee.			1	-	-	-		-	-	-	-	-	-	-	
216	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		214	Amount as approved by the Audit Committee.			214	-	-	-		-	-	-	-	-	-	-	
217	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest paid		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
218	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			440	-	-	-		-	-	-	-	-	-	-	
219	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	6	Amount as approved by the Audit Committee.			6	-	-	-		-	-	-	-	-	-	-	
220	Zydus Wellness Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
221	Zydus Wellness Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Any other transaction	Director Sitting Fees	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
222	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.			7	-	-	-		-	-	-	-	-	-		
223	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Remuneration		-	N.A.			10	-	-	-		-	-	-	-	-	-		
224	Zydus Wellness Limited	Mr. Nandish P. Joshi	Key Managerial Personnel	Remuneration		-	N.A.			1	-	-	-		-	-	-	-	-	-		
225	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest received		-	N.A.			20	-	-	-		-	-	-	-	-	-		
226	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Interest received		-	N.A.			7	-	-	-		-	-	-	-	-	-		
227	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Loan		-	N.A.			53	-	-	-		-	-	Loans	6 Month SOFR + 150 BPS	2 Year	Unsecured	Business Purpose	
228	Zydus Pharmaceuticals Limited	Zydus Pharmaceuticals Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			7	-	-	-		-	-	-	-	-	-		
229	Zydus Wellness Limited	Zydus Wellness Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			5	-	-	-		-	-	-	-	-	-		
230	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	-	-		-	-	-	-	-	-		
231	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1	5	-		-	-	-	-	-	-		
232	Zydus Wellness Limited	Mr. Nandish P. Joshi	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	-	-		-	-	-	-	-	-		
233	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	2,058	-	-		-	-	-	-	-	-		
234	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	196	243	-		-	-	-	-	-	-		
235	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	44	-		-	-	-	-	-	-		
236	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	-	440	-		-	-	-	-	-	-		
237	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	124	-	-		-	-	-	-	-	-		
238	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	20	35	-		-	-	-	-	-	-		

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
239	Zydus Wellness Products Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
240	Zydus Wellness Products Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-	-	
241	Zydus Wellness Products Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.			52	-	-	-		-	-	-	-	-	-	-	
242	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		-	N.A.			96	-	-	-		-	-	-	-	-	-	-	
243	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		-	N.A.			45	-	-	-		-	-	-	-	-	-	-	
244	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
245	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		-	N.A.			5	-	-	-		-	-	-	-	-	-	-	
246	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			21	-	-	-		-	-	-	-	-	-	-	
247	Zydus Wellness Products Limited	LM Manufacturing India Private Limited	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
248	Zydus Wellness Products Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
249	Zydus Wellness Products Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-	
250	Zydus Wellness Products Limited	Heinz India Private Limited Provident Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
251	Zydus Wellness Products Limited	Heinz India Private Limited Employee Provident Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
252	Zydus Wellness Products Limited	Heinz India Private Limited Pension Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
253	Zydus Wellness Products Limited	Zydus Wellness Sikkim Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			5	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
254	Zydus Wellness Products Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	2	-	-		-	-	-	-	-	-		
255	Zydus Wellness Products Limited	Mr. Tarun Arora	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	3	-	-		-	-	-	-	-	-		
256	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	187	214	-		-	-	-	-	-	-		
257	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	30	20	-		-	-	-	-	-	-		
258	German Remedies Pharma Private Limited	German Remedies Pharmaceuticals Private Limited Emp Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.			5	-	-	-		-	-	-	-	-	-		
259	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		-	N.A.			176	-	-	-		-	-	-	-	-	-		
260	German Remedies Pharma Private Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Corporate Social Responsibility (CSR) Expenses	-	N.A.			12	-	-	-		-	-	-	-	-	-		
261	German Remedies Pharma Private Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	Share of profit Received	-	N.A.			0	-	-	-		-	-	-	-	-	-		
262	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	56	3	-		-	-	-	-	-	-		
263	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			16	-	-	-		-	-	-	-	-	-		
264	Zydus Pharmaceuticals Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-		
265	Zydus Pharmaceuticals Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		-	N.A.			15	-	-	-		-	-	-	-	-	-		
266	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	10	5	-		-	-	-	-	-	-		
267	Zydus Pharmaceuticals Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	49	15	-		-	-	-	-	-	-		

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
268	Zydus Animal Health and Investments Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
269	Zydus Animal Health and Investments Limited	Dialforhealth Unity Limited	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
270	Zydus Animal Health and Investments Limited	Dialforhealth Unity Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
271	Zydus Animal Health and Investments Limited	Sterling Biotech Limited	Joint Ventures	Investment		-	N.A.			208	6,500	6,708	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
272	Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Subsidiary Company	Investment		-	N.A.			-	419	-	-		-	-	-	-	-	-	-	
273	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Investment		-	N.A.			150	245	-	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
274	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Investment		-	N.A.			395	-	-	-		-	-	-	-	-	-	-	
275	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Interest received		-	N.A.			29	-	-	-		-	-	-	-	-	-	-	
276	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Loan		-	N.A.			371	-	-	-		-	-	Loans	1 Month T Bill + 120 BPS	5 Year	Unsecured	Business Purpose	
277	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	4	-	-		-	-	-	-	-	-	-	
278	Zydus Animal Health and Investments Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
279	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Sale of goods or services		-	N.A.			877	-	-	-		-	-	-	-	-	-	-	
280	Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Subsidiary Company	Interest received		-	N.A.			11	-	-	-		-	-	-	-	-	-	-	
281	Zydus Animal Health and Investments Limited	Zydus Foundation	Subsidiary Company	Any other transaction	Corporate Social Responsibility (CSR) Expenses	-	N.A.			18	-	-	-		-	-	-	-	-	-	-	
282	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	51	173	-		-	-	-	-	-	-	-	
283	Zydus Animal Health and Investments Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
284	Zydus Animal Health and Investments Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	2	-		-	-	-	-	-	-	-	
285	Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	419	427	-		-	-	-	-	-	-	-	
286	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	647	1,033	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
													Amount in INR Million except stated otherwise									
													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
287	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	932	860	-		-	-	-	-	-	-	-	
288	Recon Pharmaceuticals and Investments	Zydus Foundation	Subsidiary Company	Interest received		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
289	Recon Pharmaceuticals and Investments	Zydus Medtech Private Limited	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
290	Recon Pharmaceuticals and Investments	Zydus Foundation	Subsidiary Company	Investment		-	N.A.			900	-	-	-		-	-	-	-	-	-	-	
291	Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			90	-	-	-		-	-	-	-	-	-	-	
292	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			63	-	-	-		-	-	-	-	-	-	-	
293	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			219	-	-	-		-	-	-	-	-	-	-	
294	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			270	-	-	-		-	-	-	-	-	-	-	
295	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
296	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
297	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
298	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Purchase of goods or services		-	N.A.			4,694	-	-	-		-	-	-	-	-	-	-	
299	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			123	-	-	-		-	-	-	-	-	-	-	
300	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			686	-	-	-		-	-	-	-	-	-	-	
301	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	2,775	4,357	-		-	-	-	-	-	-	-	
302	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
303	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses paid	-	N.A.			8	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																					
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																					
												Amount in INR Million except stated otherwise									
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments			
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
304	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	
305	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			2	-	-	-		-	-	-	-	-	-	
306	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			4	-	-	-		-	-	-	-	-	-	
307	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			2	-	-	-		-	-	-	-	-	-	
308	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	
309	Zydus Pharmaceuticals (USA) Inc.	Mahadev Management Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			65	-	-	-		-	-	-	-	-	-	
310	Zydus Pharmaceuticals (USA) Inc.	Zydus Healthcare (USA) LLC	Subsidiary Company	Interest received		-	N.A.			6	-	-	-		-	-	-	-	-	-	
311	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.			96	-	-	-		-	-	-	-	-	-	
312	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Interest received		-	N.A.			20	-	-	-		-	-	-	-	-	-	
313	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Interest received		-	N.A.			2	-	-	-		-	-	-	-	-	-	
314	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Interest received		-	N.A.			176	-	-	-		-	-	-	-	-	-	
315	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	
316	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Interest received		-	N.A.			1	-	-	-		-	-	-	-	-	-	
317	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Loan		-	N.A.			42	-	-	-		-	-	Loans	3 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
318	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	8	51	-		-	-	-	-	-	-	
319	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	1	-		-	-	-	-	-	-	
320	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Loan		-	N.A.			187	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
321	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Loan		-	N.A.			364	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
322	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Loan		-	N.A.			1,589	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
323	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Loan		-	N.A.			729	-	-	-		-	-	Loans	6 Month SOFR + 50 BPS	1 Year	Unsecured	Business Purpose
324	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Loan		-	N.A.			4,700	-	-	-		-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
325	Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-		-	16	-		-	-	-	-	-	-	
326	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-		-	0	-		-	-	-	-	-	-	
327	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	18	46	-		-	-	-	-	-	-	-	
328	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-		-	89	-		-	-	-	-	-	-	
329	Zydus Pharmaceuticals (USA) Inc.	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	9,176	-	-	-		-	-	-	-	-	-	
330	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	6,716	2,765	-		-	-	-	-	-	-	-	
331	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	738	941	-		-	-	-	-	-	-	-	
332	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	-	368	-		-	-	-	-	-	-	-	
333	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	6,404	8,120	-		-	-	-	-	-	-	-	
334	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	2	33	-		-	-	-	-	-	-	-	
335	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	61	8	-		-	-	-	-	-	-	-	
336	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	4	-		-	-	-	-	-	-	-	
337	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	30	33	-		-	-	-	-	-	-	-	
338	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			522	-	-	-		-	-	-	-	-	-	-	
339	Zydus Worldwide DMCC	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			4	-	-	-		-	-	-	-	-	-	-	
340	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		-	N.A.			546	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
341	Zydus Worldwide DMCC	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-	-	
342	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.			25	-	-	-		-	-	-	-	-	-	-	
343	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Interest received		-	N.A.			14	-	-	-		-	-	-	-	-	-	-	
344	Zydus Worldwide DMCC	Etna Biotech S.R.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	70	-	-		-	-	-	-	-	-	-	
345	Zydus Worldwide DMCC	Etna Biotech S.R.L.	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-	
346	Zydus Worldwide DMCC	Zydus France, SAS	Subsidiary Company	Interest received		-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
347	Zydus Worldwide DMCC	Zydus France, SAS	Subsidiary Company	Loan		-	N.A.			211	-	-	-		-	-	Loans	6 Month EURIBOR + 125 BPS	5 Year	Unsecured	Business Purpose	
348	Zydus Worldwide DMCC	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	-	216	-		-	-	-	-	-	-	-	
349	Zydus Worldwide DMCC	Etna Biotech S.R.L.	Subsidiary Company	Loan		-	N.A.			22	-	-	-		-	-	Loans	6 Month SOFR + 125 BPS	5 Year	Unsecured	Business Purpose	
350	Zydus Worldwide DMCC	Zydus International Private Limited	Subsidiary Company	Interest received		-	N.A.			229	-	-	-		-	-	-	-	-	-	-	
351	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	528	553	-		-	-	-	-	-	-	-	
352	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	938	982	-		-	-	-	-	-	-	-	
353	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	206	-	-		-	-	-	-	-	-	-	
354	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1,571	288	-		-	-	-	-	-	-	-	
355	Viona Pharmaceuticals INC	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
356	Viona Pharmaceuticals INC	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
357	Viona Pharmaceuticals INC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-	
358	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		-	N.A.			19	-	-	-		-	-	-	-	-	-	-	
359	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		-	N.A.			3	-	-	-		-	-	-	-	-	-	-	
360	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
361	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	210	214	-		-	-	-	-	-	-	-	
362	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	1	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
													Amount in INR Million except stated otherwise									
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
363	Zydus Healthcare (USA) LLC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	2	0	-		-	-	-	-	-	-	-	
364	ZyVet Animal Health Inc	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			201	-	-	-		-	-	-	-	-	-	-	
365	Zydus Wellness International DMCC	Zydus Worldwide DMCC	Subsidiary Company	Purchase of goods or services		-	N.A.			1	-	-	-		-	-	-	-	-	-	-	
366	Zydus Wellness International DMCC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	1	-		-	-	-	-	-	-	-	
367	Zydus International Private Limited	RIC Chemicals LTD	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			2	-	-	-		-	-	-	-	-	-	-	
368	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-	
369	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Interest received		-	N.A.			5	-	-	-		-	-	-	-	-	-	-	
370	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Interest received		-	N.A.			8	-	-	-		-	-	-	-	-	-	-	
371	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Interest received		-	N.A.			6	-	-	-		-	-	-	-	-	-	-	
372	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Loan		-	N.A.			3,716	-	-	-		-	-	-	-	-	-	-	
373	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.			3,716	-	-	-		-	-	-	-	-	-	-	
374	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.			239	-	-	-		-	-	-	-	-	-	-	
375	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	8,801	5,421	-		-	-	-	-	-	-	-	
376	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Loan		-	N.A.			684	-	-	-		-	-	-	-	-	-	-	
377	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Interest received		-	N.A.			478	-	-	-		-	-	-	-	-	-	-	
378	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	17,771	17,115	-		-	-	-	-	-	-	-	
379	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	8,947	5,417	-		-	-	-	-	-	-	-	
380	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	252	256	-		-	-	-	-	-	-	-	
381	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	365	368	-		-	-	-	-	-	-	-	
382	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	450	455	-		-	-	-	-	-	-	-	
383	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	334	338	-		-	-	-	-	-	-	-	
384	Zydus France, SAS	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
385	Zydus France, SAS	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			1	-	-	-	-	-	-	-	-	-	-	-	
386	Zydus France, SAS	Laboratorios Comib S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-	-	-	-	-	-	-	-	-	
387	Zydus Healthcare S.A. (Pty) Ltd	Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	440	421	-	-	-	-	-	-	-	-	-	
388	Zydus Healthcare S.A. (Pty) Ltd	Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	53	51	-	-	-	-	-	-	-	-	-	
389	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		-	N.A.			312	-	-	-	-	-	-	-	-	-	-	-	
390	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-	-	-	-	-	-	-	-	-	
391	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	3	7	-	-	-	-	-	-	-	-	-	
392	Zydus Pharmaceuticals Mexico SA De CV	Zydus Pharmaceuticals Mexico Services Company SA De C.V.	Subsidiary Company	Purchase of goods or services		-	N.A.			0	-	-	-	-	-	-	-	-	-	-	-	
393	Zydus Healthcare Philippines Inc.	RJ Conception Law Office	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			0	-	-	-	-	-	-	-	-	-	-	-	
394	Alidac Healthcare (Myanmar) Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			0	-	-	-	-	-	-	-	-	-	-	-	
395	Alidac Healthcare (Myanmar) Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			0	-	-	-	-	-	-	-	-	-	-	-	
396	Alidac Healthcare (Myanmar) Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	1	-	-	-	-	-	-	-	-	-	
397	Zynext Ventures Pte. Ltd.	Zynext Ventures USA LLC	Subsidiary Company	Investment		-	N.A.			427	354	781	-	-	-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
398	Zynext Ventures USA LLC	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			1	-	-	-	-	-	-	-	-	-	-	-	
399	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Interest received		-	N.A.			26	-	-	-	-	-	-	-	-	-	-	-	
400	Zydus Pharmaceuticals UK Ltd.	Medsolutions (Europe) Limited	Subsidiary Company	Interest received		-	N.A.			0	-	-	-	-	-	-	-	-	-	-	-	
401	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Interest received		-	N.A.			57	-	-	-	-	-	-	-	-	-	-	-	
402	Zydus Pharmaceuticals UK Ltd.	Oncosol Limited	Joint Ventures	Interest received		-	N.A.			0	-	-	-	-	-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
403	Zydus Pharmaceuticals UK Ltd.	LiqMeds Worldwide Limited	Subsidiary Company	Interest paid		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
404	Zydus Pharmaceuticals UK Ltd.	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	1	-		-	-	-	-	-	-	-	
405	Zydus Pharmaceuticals UK Ltd.	Oncosol Limited	Joint Ventures	Loan		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
406	Zydus Pharmaceuticals UK Ltd.	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-	
407	Zydus Pharmaceuticals UK Ltd.	Medsolutions (Europe) Limited	Subsidiary Company	Loan		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
408	Zydus Pharmaceuticals UK Ltd.	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	0	-	-		-	-	-	-	-	-	-	
409	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	9	-		-	-	-	-	-	-	-	
410	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	1,840	1,704	-		-	-	-	-	-	-	-	
411	Zydus Pharmaceuticals UK Ltd.	LiqMeds Worldwide Limited	Subsidiary Company	Loan		-	N.A.			20	-	-	-		-	-	-	-	-	-	-	
412	Zydus Pharmaceuticals UK Ltd.	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.			-	22	-	-		-	-	-	-	-	-	-	
413	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.			-	830	769	-		-	-	-	-	-	-	-	
414	Zydus Lifesciences Global FZE [UAE]	Zydus Lifesciences Limited	Parent Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	1,044	3,084	-		-	-	-	-	-	-	-	
415	Zydus Lifesciences Global FZE [UAE]	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.			225	-	-	-		-	-	-	-	-	-	-	
416	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services		-	N.A.			85	-	-	-		-	-	-	-	-	-	-	
417	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			15	-	-	-		-	-	-	-	-	-	-	
418	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	7	1	-		-	-	-	-	-	-	-	
419	Zydus Lifesciences Global FZE [UAE]	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	128	166	-		-	-	-	-	-	-	-	
420	LM Manufacturing Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			9	-	-	-		-	-	-	-	-	-	-	
421	LM Manufacturing Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		-	N.A.			7	-	-	-		-	-	-	-	-	-	-	
422	LiqMeds Worldwide Limited	LM Manufacturing Limited	Subsidiary Company	Sale of goods or services		-	N.A.			9	-	-	-		-	-	-	-	-	-	-	
423	LiqMeds Worldwide Limited	LiqMeds Lifecare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
424	LiqMeds Worldwide Limited	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	18	-		-	-	-	-	-	-	-	
425	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Sale of goods or services		-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
426	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.			0	-	-	-		-	-	-	-	-	-	-	
427	LiqMeds Lifecare Limited	Oncosol Limited	Joint Ventures	Sale of goods or services		-	N.A.			93	-	-	-		-	-	-	-	-	-	-	
428	LM Manufacturing India Private Limited	LM Manufacturing Limited	Subsidiary Company	Sale of goods or services		-	N.A.			35	-	-	-		-	-	-	-	-	-	-	
429	LiqMeds Worldwide Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	437	937	-		-	-	-	-	-	-	-	
430	LiqMeds Worldwide Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	0	0	-		-	-	-	-	-	-	-	
431	LM Manufacturing Limited	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	-	2	-		-	-	-	-	-	-	-	
432	LM Manufacturing Limited	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	6	-	-		-	-	-	-	-	-	-	
433	LM Manufacturing Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	9	-		-	-	-	-	-	-	-	
434	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	8	8	-		-	-	-	-	-	-	-	
435	LiqMeds Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	230	340	-		-	-	-	-	-	-	-	
436	LiqMeds Limited	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	57	-	-		-	-	-	-	-	-	-	
437	LiqMeds Lifecare Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	26	37	-		-	-	-	-	-	-	-	
438	LM Manufacturing India Private Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	13	-		-	-	-	-	-	-	-	
439	LiqMeds Lifecare Limited	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	1	1	-		-	-	-	-	-	-	-	
440	LiqMeds Lifecare Limited	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	10	10	-		-	-	-	-	-	-	-	

Zydus Lifesciences Limited																						
Disclosure of related party transactions for the half year/ six months ended March 31, 2025																						
												Amount in INR Million except stated otherwise										
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
441	LiqMeds Lifecare Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	4	117	-		-	-	-	-	-	-		
442	Medsolutions (Europe) Limited	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	13	13	-		-	-	-	-	-	-		
443	Medsolutions (Europe) Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	0	-		-	-	-	-	-	-		
444	Medsolutions (Europe) Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.			-	0	-	-		-	-	-	-	-	-		
445	Zydus Medtech Private Limited	Zydus Medtech France SAS	Subsidiary Company	Investment		-	N.A.			0	-	0	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
446	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Interest received		-	N.A.			2	-	-	-		-	-	-	-	-	-		
447	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Loan		-	N.A.			1,269	-	-	-		-	-	Loans	1 Month SOFR + 125 BPS	1 Month	Unsecured	Business Purpose	
448	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Loan		-	N.A.			1,269	-	-	-		-	-	-	-	-	-		
449	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimbursement of Expenses paid	-	N.A.			37	-	-	-		-	-	-	-	-	-		
450	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.			-	-	1,249	-		-	-	-	-	-	-		
451	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of fixed assets		-	N.A.			1,184	-	-	-		-	-	-	-	-	-		
452	Zydus Healthcare S.A. (Pty) Ltd	DI Consultancy	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.			8	-	-	-		-	-	-	-	-	-		
453	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.			1,970	-	-	-		-	-	-	-	-	-		
454	Zydus Foundation	AIA Engineering Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Contributions received	-	N.A.			5	-	-	-		-	-	-	-	-	-		
455	Zydus Foundation	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Contributions received	-	N.A.			2	-	-	-		-	-	-	-	-	-		
456	Zydus Foundation	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Contributions received	-	N.A.			10	-	-	-		-	-	-	-	-	-		

Zydus Lifesciences Limited																			Amount in INR Million except stated otherwise				
Disclosure of related party transactions for the half year/ six months ended March 31, 2025												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments					Details of loans/ investments					
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)		
457	Zydus Foundation	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Contributions received	-	N.A.			4	-	-	-		-	-	-	-	-	-	-		
458	Zydus Foundation	Zydus Takeda Healthcare Private Limited	Joint Ventures	Any other transaction	Contributions received	-	N.A.			25	-	-	-		-	-	-	-	-	-	-		

- Notes:
- Amount mentioned as 0 denotes value less than INR 1 Million.
 - Opening and closing balance are not given where there was no transaction of Investment during the half year ended March 31, 2025.
 - Receivables / Payables other than loans represents combined balance against sales / purchase pertaining to goods/ propoerty, plant and equipment / various services / reimbursement of expenses. Hence shown separately.